Abstract: Type 2 diabetes mellitus has become an epidemic with rapidly increasing prevalence worldwide. While strict glycemic control has been shown to reduce the risk of diabetic microvascular complications, its role in preventing cardiovascular disease has been less clear. Indeed, anti-hyperglycemic therapies have historically been neutral for cardiovascular benefit. However, recent cardiovascular outcome trials utilizing sodium glucose transporter 2 inhibitors across a broad spectrum of cardiovascular disease patients have demonstrated significant mortality benefit resulting in a paradigm shift in the approach towards patients with heart disease and diabetes mellitus.
Introduction
Type 2 diabetes mellitus (T2DM) has become an epidemic with rapidly increasing prevalence worldwide. 1, 2 It is associated with microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (myocardial infarction (MI), congestive heart failure (CHF) and stroke) complications. 3 While strict glycemic control has been shown to reduce the risk of diabetic microvascular complications, its role in preventing cardiovascular disease (CVD) has been less clear. 4, 5 Indeed, antihyperglycemic therapies have historically been neutral for cardiovascular (CV) benefit, and all new anti-hyperglycemic agents are evaluated in large clinical trials to ensure CV safety, since observation of increased mortality risk associated with thiazolidinediones use in patients with CVD. Sodium glucose co-transporter 2 inhibitors (SGLT2) are marking a new era in the treatment of T2DM after showing significant mortality benefit in patients with CVD. The objective of this narrative review is to discuss the pathophysiology of how SGLT2 may reduce CV outcomes and provide an overview of the current evidence for this therapy.
Glycemic control in T2DM
The management of patients with diabetes is multifaceted and requires an interdisciplinary approach with lifestyle changes, assessment for micro-and macrovascular complications, prevention of hyperglycemia, and monitoring of CV risk. Suboptimal glycemic control with a glycated hemoglobin (A1C) level >7% is associated with an increase in microvascular and CV complications. 6, 7 In contrast, strict glycemic control in the UK Prospective Diabetes Study (UKPDS) trial was associated with a significant reduction in the risk of microvascular complications, but had no significant beneficial effect on CV outcomes. 6 More recent randomized Anti-hyperglycemic treatment regimens and targets need to be individualized for each patient. With a growing list of available agents, there are many antihyperglycemic combinations to achieve the therapeutic A1C target. Metformin is generally the initial therapy due to its low cost, safety profile, and possible CV benefits, unless there are contraindications. 9 If the A1C target is not achieved with monotherapy, a second-line antihyperglycemic agent (dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, SGLT2 inhibitors, insulin secretagogues, thiazolidinediones, and insulin) can be added. The choice of a specific anti-hyperglycemic agent will depend on multiple factors, including the severity of hyperglycemia, patient comorbidities, side-effect profile (such as hypoglycemia, weight gain), cost considerations, and patient preference.
SGLT2 inhibitors and glucose metabolism
The kidneys play a critical role in glucose regulation via gluconeogenesis and glucose reabsorption from the glomerular filtrate. 10 Renal glucose reabsorption occurs via two SGLT channels (SGLT1 and SGLT2) located in the proximal tubule. 11 SGLT2 is responsible for approximately 90% of glucose reabsorption, while SGLT1 accounts for the remaining 10%. 11 In a healthy kidney, 99% of glucose is reabsorbed and very little is present in the urine. 10 However, in patients with T2DM, plasma glucose levels exceed the maximum glucose transport capacity, leading to glycosuria. This results in up-regulated SGLT genes, increased renal glucose reabsorption, and further hyperglycemia, thus making SGLT2 a logical target in the management of T2DM. Currently, three SGLT2 inhibitors are commercially available, and include empagliflozin (Jardiance, Boehringer Ingelheim and Eli Lilly), canagliflozin (Invokana, Janssen), and dapagliflozin (Forxiga, Bristol-Myers Squibb, and AstraZeneca).
EMPA-REG OUTCOME trial
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) was a large multi-center randomized double-blind, placebo-controlled trial (Table 1) 12 designed to examine CV morbidity and mortality outcomes with empagliflozin compared to placebo in patients with T2DM at high risk of CV events. This intention to treat analysis compared pooled empagliflozin (10 mg and 25 mg groups) vs placebo using a four-step hierarchical-testing strategy to assess for non-inferiority and superiority. All eligible patients underwent a 2-week placebo run in period before being randomized to empagliflozin 10 mg once daily, empagliflozin 25 mg once daily, or placebo once daily. Between 2010-2013, 11,531 patients were assessed for eligibility and 7,028 patients underwent randomization. Of the 39% of potentially eligible patients excluded, 85% did not meet the inclusion/exclusion criteria. The two groups were well-matched with no statistically significant difference in baseline characteristics. The mean age was 63±9 years, and 72% were male. The mean A1C was 8.08 ±0.85%, 57% of patients had diabetes for more than 10 years, and 48% of patients were on insulin. The majority of patients (95%) were treated with anti-hypertensive medications, with 80% on angiotensin-converting enzyme inhibitor or angiotensin receptor blockers. Also, 77% of patients were on statin therapy and 83% were on aspirin.
The primary outcome of CV death, non-fatal MI or nonfatal stroke (Table 2 ) was significantly reduced in the pooled empagliflozin group (12.1%) compared to placebo (10.5%) with HR=0.86 (95% confidence interval (CI)=0.74-0.99). Based on the Kaplan-Meier curve, the outcomes appear to separate early by 3 months of treatment. When the individual components of the primary outcome are examined, CV mortality was significantly reduced (3.7% empagliflozin vs 5.9% placebo, HR=0.62, 95% CI=0.49-0.77, P<0.001), whereas non-fatal MI (4.5% empagliflozin vs 5.2% placebo, HR=0.87, 95% CI=0.70-1.09, P=0.22) and stroke (3.2% empagliflozin vs 2.6% placebo, HR=1.24, 95% CI=0.92-1.67, P=0.16) were not significantly different. Hospitalization for CHF, (2.7% empagliflozin vs 4.1% placebo, HR=0.65, 95% CI=0.50-0.85, P=0.002) and all-cause mortality (5.7% empagliflozin vs 8.3% placebo, HR=0.68, 95% CI=0.57-0.82, P<0.001) were also significantly reduced with empagliflozin compared to placebo.
The rate of any adverse event in the study was high (90% empagliflozin vs 92% placebo, P<0.001), but rates EMPA-REG OUTCOME was a well-designed RCT, and its results have been practice changing specifically as it relates to the management of CV risk in patients with T2DM. This study showed significant mortality benefit (both CV and all-cause) as well as a reduction in hospitalization for CHF. The number needed to treat for the primary outcome (composite of CV death, non-fatal MI, and stroke) was 63 patients over 3.1 years, a benefit mainly driven by reduction of CV death. Similarly, the HR for hospitalization from CHF was significantly lower (HR=0.66, 95% CI=0.55-0.79) with an absolute risk reduction of 1.4% and a number needed to treat of 71 over 3.1 years.
The mechanism of CV benefit with SGLT2 inhibitors
It is interesting to note that the clinical benefit of SGLT2 inhibitors in reducing CV morbidity and mortality was seen early after treatment initiation and exceeds the benefit expected from modest improvement observed in the metabolic profile of treated patients. In addition to a 0.3% difference of A1C levels between the study and the control arm at study end, the empagliflozin group in the EMPA-REG OUTCOME trial demonstrated only a mild reduction in systolic and diastolic blood pressure measurements, moderate weight reduction, and lower uric acid levels throughout the study period. However, the clinical benefit of empagliflozin was seen as early as 3 months after initiation of treatment, strongly suggesting an independent mechanism of cardio-protection in treated patients.
Proposed mechanisms for the cardioprotective of empagliflozin include reduction in cardiac inflammation, 13 decreased cardiac oxidative stress, 14 decreased cardiac apoptosis, 15 and improved cardiac mitochondrial function. 14 Recently reported results from the Effects of Empagliflozin on Cardiac Structure in Patients with Type 2 Diabetes (EMPA-HEART) trial identified a significant reduction in left ventricular mass index on cardiac magnetic resonance at 6 months in the empagliflozin group compared to placebo (−2.6 vs −0.01 gm/m 2 , P=0.01) suggesting the beneficial effects on left ventricular remodeling. 16 In addition, treatment with empagliflozin may also improve cardiac energy metabolism via increased glucose and fatty acid oxidation translating into a cardioprotective effect for patients with heart failure. 17 However, further mechanistic studies are needed to better elucidate the remarkable results observed in the EMPA-REG OUTCOME trial. Additional studies examining the efficacy and safety of other SGLT2 inhibitors, canagliflozin 18 and dapagliflozin, 19 have demonstrated CV outcome benefits that are consistent with the EMPA-REG OUTCOME study confirming that CV protection is indeed a class effect rather than characteristic of a specific compound.
CANVAS and DECLARE trials
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS) 18 integrated data from two RCTs (CANVAS and CANVAS-R) to examine the effects of treatment with canagliflozin on 10,142 patients with T2DM and high risk of CVD. Baseline characteristics are shown in Table 1 . The primary outcome (composite of death from CV cause, non-fatal MI, or non-fatal stroke) was lower with canagliflozin than placebo (2.69% vs 3.15%, HR=0.86, 95% CI=0.75-0.97). Similar to EMPA-REG OUTCOME, there was a reduction in CHF with canagliflozin compared to placebo (0.55% vs 0.87%, HR=0.67, 95% CI=0.52-0.87), but, unlike EMPA-REG OUTCOME, CV death (1.2% vs 1.3%, HR=0.87, 95% CI=0.72-1.06) and all-cause death (1.2% vs 1.3%, HR=0.94, 95% CI=0.88-1.00) were not reduced. This is likely due to differences in the inclusion criteria -EMPA-REG OUTCOME included patients with established CVD, whereas CANVAS included patients without symptomatic CVD but at least two CV risk factors. This lower risk patient population led to lower event rates and, overall, less power to detect a difference between the two groups. A network meta-analysis of nine large CV outcome trials of new antidiabetic drugs included two SGLT2 trials (EMPA-REG OUTCOME and CANVAS), but not the more recent DECLARE TIMI 58. 20 The meta-analysis demonstrated a 28% reduction in CHF hospitalization events with SGLT2 therapy compared to placebo (risk ratio=0.72, 95% CI=0.6-0.86). Ranking for the network meta-analysis showed empagliflozin ranked first in reducing major adverse cardiovascular events, CV death, nonfatal MI, death from any cause and CHF hospitalizations, compared to canagliflozin. Another meta-analysis included all three SGLT2 RCTs, but only assessed CHF outcomes which demonstrated a significant reduction in hospitalizations for CHF (odds ratio=0.70, 95% CI=0.61-0.79). 21 However, an updated meta-analysis including all SGLT2 RCTs would be helpful to assess the potential benefits for important clinical outcomes.
Conclusion
Recent trials that included T2DM patients across a spectrum of CV risk have demonstrated significant CV benefit with SGLT2 inhibitors resulting in a paradigm shift for the management of these high risk patients. Although additional studies are required to better understand the mechanism underlying observed CV risk modification, the clinical implications for an individual patient cannot be ignored. Therefore, SGLT2 inhibitors should be a part of the therapeutic regimen for all eligible T2DM patients with established CVD and strongly considered for those T2DM patients at high risk of future CV events.
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